Bullich, Santiago http://orcid.org/0000-0001-5669-269X
Roé-Vellvé, Núria
Marquié, Marta
Landau, Susan M.
Barthel, Henryk
Villemagne, Victor L.
Sanabria, Ángela
Tartari, Juan Pablo
Sotolongo-Grau, Oscar
Doré, Vincent
Koglin, Norman
Müller, Andre
Perrotin, Audrey
Jovalekic, Aleksandar
De Santi, Susan
Tárraga, Lluís
Stephens, Andrew W.
Rowe, Christopher C.
Sabri, Osama
Seibyl, John P.
Boada, Mercè
Funding for this research was provided by:
Bayer Pharma AG or Piramal Imaging
Fundació ACE Institut Català de Neurociències Aplicades, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa
EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (115952)
Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904, Department of Defense award number W81XWH-12-2-0012)
Article History
Received: 23 December 2020
Accepted: 10 March 2021
First Online: 27 March 2021
Declarations
:
: All studies were conducted in accordance with the Declaration of Helsinki and after approval of the local ethics committees of the participating centers. All participants (or their legal representatives) provided written informed consent prior to recruitment.
: Not applicable.
: SB, NRV, NK, AM, AP, AJ, and AS are employees of Life Molecular Imaging GmbH (formerly Piramal Imaging GmbH). SDS is an employee of Eisai Inc. and a former employee of Life Molecular Imaging Inc. (formerly Piramal Pharma Inc). HB and OS received research support, consultant honoraria, and travel expenses from Piramal Imaging GmbH. Victor L. Villemagne has received speaker’s honoraria from Piramal Imaging, GE Healthcare, Avid Pharmaceuticals, AstraZeneca, and Hoffmann-La Roche and consulting fees for Novartis, Lundbeck, Abbvie, Shanghai Green Valley Pharmaceutical Co. LTD, and Hoffmann-La Roche. Christopher C. Rowe has received research grants from Bayer Schering Pharma, Piramal Imaging, Avid Radiopharmaceuticals, Navidea, GE Healthcare, AstraZeneca, and Biogen. John Seibyl holds equity in Invicro and consulting fees from LMI, Roche, Biogen, AbVie, and Invicro. M. Boada has received research funds from the following private donors: Grifols SA, Caixabank S.A., Piramal Imaging, Araclon Biotech, Laboratorios Echevarne, Fundació Castell de Peralada, and Fundació La Pedrera and has participated in advisory boards of Araclon Biotech, Biogen, Bioibérica, Eisai, Grifols, Lilly, Merck, Nutricia, Roche, Schwabe Farma, Servier, and Kyowa Kirin.No other potential conflict of interest relevant to this article was reported.